Please try another search
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Jon P. Stonehouse | 60 | 2007 | CEO, President & Executive Director |
Nancy June Hutson | 74 | 2012 | Independent Chair |
Theresa Marie Heggie | 64 | 2018 | Independent Director |
Alan G. Levin | 62 | 2020 | Independent Director |
Steven K. Galson | 67 | 2021 | Independent Director |
Machelle Sanders | 61 | 2022 | Independent Director |
Amy E. McKee | 52 | 2021 | Independent Director |
Stephen J. Aselage | 73 | 2019 | Independent Director |
Vincent J. Milano | 60 | 2021 | Independent Director |
George B. Abercrombie | 69 | 2011 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review